Changing epidemiology of hepatocellular carcinoma in Singapore - a study of 1,401 cases over 3 decades
AASLD LiverLearning®, Weiquan James Li, 144138
Effects of BMS-986036 (pegylated fibroblast growth factor 21) on hepatic steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis
AASLD LiverLearning®, John Krupinski, 144394
A novel serum biomarker, clusterin, could be an early predictor of response to sorafenib
AASLD LiverLearning®, Takehisa Watanabe, 144139
Inhibition of sphingosine 1-phosphate signaling by FTY720 ameliorates murine nonalcoholic steatohepatitis
AASLD LiverLearning®, Amy Mauer, 144395
Geographic variation and provider characteristics affect receipt of curative therapy in early stage hepatocellular carcinoma: a Veteran cohort study.
AASLD LiverLearning®, Marina Serper, 144140
Mixed lineage kinase 3 mediates the induction of CXCL10 by a STAT1-dependent mechanism during hepatocyte lipotoxicity
AASLD LiverLearning®, Kyoko Tomita, 144396
Development of a Novel Circulating Tumor Cells Isolation System in Patients with Hepatocellular Carcinoma Using a Microcavity Array
AASLD LiverLearning®, Kazuto Takahashi, 144153
Hepatocellular Carcinoma in Patients Cured of Hepatitis C Virus: Less Cirrhosis and Liver Fat than Expected
AASLD LiverLearning®, James Crismale, 144154
Connexin 32 is a critical gatekeeper at the nexus between inflammation and steatosis in ALD and NAFLD
AASLD LiverLearning®, Jay Luther, 144410
Decision Making for Surveillance Interval: Who May Extend Intervals 1 Year After Curative Treatments for Hepatocellular Carcinoma
AASLD LiverLearning®, Minjong Lee, 144155
Second Harmonic Generation microscopy: a novel automated method for quantification of hepatic steatosis in chronic liver disease.
AASLD LiverLearning®, George Boon Bee Goh, 144411
A Novel Biomarker-Based Model for the Prediction of Response to Sorafenib and Overall Survival for Advanced Hepatocellular Carcinoma: A Prospective Cohort Study
AASLD LiverLearning®, Hwi Young Kim, 144156
CXCR3-/- mice are protected against nutrient excess diet-induced non-alcoholic steatohepatitis
AASLD LiverLearning®, Kyoko Tomita, 144412
ALBI-T: A Score Based on Albumin, Bilirubin and TNM Stratifies Patients with Child A Cirrhosis and Hepatocellular Carcinoma
AASLD LiverLearning®, Imam Waked, 144169
Effect of Tumor Necrosis from Loco-Regional Therapy Prior to Liver Transplantation on Hepatocellular Carcinoma Recurrence after Transplant
AASLD LiverLearning®, Dilip Moonka, 144170
Obeticholic acid reduces plasma HDL-cholesterol levels and promotes transhepatic cholesterol efflux in hyperlipidemic hamsters via a mechanism involving upregulation of hepatic SR-BI
AASLD LiverLearning®, Jingwen Liu, 144426
Use of radiofrequency ablation and stereotactic body radiotherapy for the treatment of hepatocellular carcinoma: An analysis of the SEER-Medicare database
AASLD LiverLearning®, Neehar Parikh, 144171
SIRT3 Acts As a Negative Regulator of Autophagy Dictating Hepatocyte Susceptibility to Lipotoxicity
AASLD LiverLearning®, Zhenyuan Song, 144427
The Burden of Liver Cancer in the United States Population
AASLD LiverLearning®, Aynur Unalp-Arida, 144172
Modulation of HMGB1 - NF-κB translocation by curcumin treatment ameliorates liver injury in non-alcoholic steatohepatitis-hepatocellular carcinoma mouse model
AASLD LiverLearning®, MST. REJINA AFRIN, 144428
Changes in tissue and blood biomarkers upon exposure to sorafenib in patients with resectable HCC: translational evaluation in the BIOSHARE trial
AASLD LiverLearning®, Valérie Paradis, 144185
Clinicopathological Characteristics of Steatohepatitic Hepatocellular Carcinoma
AASLD LiverLearning®, Makiko Taniai, 144186
Role of microRNA-206 and microRNA-133b in facilitating insulin signaling and inhibiting lipogenesis
AASLD LiverLearning®, Guisheng Song, 144442
A cohort study of Hepatocellular Adenoma in post-menopausal women: can follow-up be safely terminated?
AASLD LiverLearning®, Anne Klompenhouwer, 144187
NOX1 Deletion Inhibits Hepatic Steatosis in db/db Model of Non-alcoholic Fatty Liver Disease
AASLD LiverLearning®, Sebastian Larion, 144443
Hepatocyte-derived osteopontin promotes the development of hepatocellular carcinoma
AASLD LiverLearning®, Chuck Blajszczak, 144188
Suppression of chromatin-remodeling component Arid1a contributes to NASH and hepatocellular carcinoma through transcriptional dysregulation of lipogenesis.
AASLD LiverLearning®, Jen-Chieh Chuang, 144444
Impact of Age, Gender, and Race/Ethnicity on Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in the U.S.
AASLD LiverLearning®, Vicky Bhagat, 144201
The Trend in Hepatitis Virus Treatment Status among Hepatocellular Carcinoma Patients with Chronic Viral Hepatitis Over the Last 15 Years
AASLD LiverLearning®, Ryosuke Tateishi, 144202
Role of hepatic dual-specificity phosphatase 14 (DUSP14/MKP6) in diet-induced hepatic insulin resistance and steatosis
AASLD LiverLearning®, Yan-Xiao Ji, 144458
Phenotypical characterization of intrahepatic cholangiocarcinomas : the more fibrous, the less pejorative.
AASLD LiverLearning®, Lorraine Blaise, 144203
Role of 12-Lipoxygenase in a Zebrafish Model of Non Alcoholic Fatty Liver Disease (NAFLD)
AASLD LiverLearning®, Niharika Samala, 144459
SCCA-IgM helps to identify patients at risk of long-term hepatocelullar carcinoma
AASLD LiverLearning®, Javier Ampuero, 144204
Targeting Mitochondrial Pyruvate Metabolism to Ameliorate Hepatic Fibrosis in a Mouse Model of NASH
AASLD LiverLearning®, Brian Finck, 144460
Quality of Life and Outcomes after Multiple Courses of Granulocyte-Colony Stimulating Factor and Growth Hormone in Patients with Decompensated Cirrhosis
AASLD LiverLearning®, Virendra Singh, 154967
Farnesoid X Receptor Agonist Obeticholic Acid Raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-induced NASH (DIN) Hamster, a Novel Preclinical Model for Evaluating Efficacy and Side effects of Drugs targeting Non-Alcoholic Liver Diseases.
AASLD LiverLearning®, Francois Briand, 154968
Defining Optimal Follow-up Intervals for Hepatocellular Carcinoma: What Should the Cost-effective Standard Be?
AASLD LiverLearning®, Janice Jou, 144217
Clinical-grade human liver mesenchymal stem cells for the treatment of NASH-Fibrosis through immunomodulation
AASLD LiverLearning®, Kris Gellynck, 154969
Unusually High HCC Rates Among Patients With HCV Cirrhosis After Treatment With Direct Acting Antivirals
AASLD LiverLearning®, Sudha Kodali, 144218
High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis
AASLD LiverLearning®, Helder Cardoso, 144219
Deferasirox prevents progression of non-alcoholic steatohepatitis in a mouse model with inhibition of heaptic fibrosis and hepatocellular ballooning
AASLD LiverLearning®, Masaaki Korenaga, 144475
APRI as a Tool to Initiate Increased Surveillance for HCC in African Americans
AASLD LiverLearning®, Paul Naylor, 144220
Pathophysiologic model of non-alcoholic fatty liver disease using precision-cut liver slices
AASLD LiverLearning®, Theerut Luangmonkong, 144476
A diet enriched in starch and oleate induces activation of NK cells and causes exaggerated suppression of de novo lipogenesis in adipose tissue, resulting in hepatic steatosis.
AASLD LiverLearning®, Caroline Duwaerts, 144477
The Expression of SALL4 and Its Clinical Significance In Hepatocellular Carcinoma.
AASLD LiverLearning®, Zhiying Xin, 144233
The features of hepatocellular carcinoma after IFN free treatment
AASLD LiverLearning®, Masataka Seike, 144234
Hepatitis B and C as Risk Factors for Early Hepatocellular Carcinoma Across South America
AASLD LiverLearning®, Jose Debes, 144235
Nutritional Wheat Amylase Trypsin Inhibitors, Activators of Toll Like Receptor 4, Exacerbate Non-Alcoholic Steatohepatitis in High Fat Diet Fed Mice
AASLD LiverLearning®, Muhammad Ashfaq Khan, 144491
MELD score higher than 14 is the safety cutoff for patients with Child Pugh B or C cirrhosis undergoing drug-eluting beads chemoembolization for hepatocellular carcinoma.
AASLD LiverLearning®, castel helene, 144236
GPR91 antagonism: A novel approach for the treatment of nonalcoholic steatohepatitis (NASH)
AASLD LiverLearning®, Dhananjay Umrani, 144492
TRPV4 prevents tissue injury in diseased fatty liver by blocking CYP2E1-mediated redox-toxicity via Kupffer cell-induced nitric oxide production
AASLD LiverLearning®, Ratanesh Seth, 144493
Predictive factors of hepatocellular carcinoma and transplant-free survival in Chinese patients with primary biliary cholangitis
AASLD LiverLearning®, Ka Shing Cheung, 144249
Rising Inpatient Healthcare Resource Utilization in Baby Boomers with Hepatocellular Carcinoma
AASLD LiverLearning®, George Cholankeril, 144250
Hepatocellular Carcinoma is Independently Associated with Increased Mortality in Patients with Cirrhosis Admitted to Intensive Care Units
AASLD LiverLearning®, Christina Lindenmeyer, 144251
Outcomes of a new very small diameter drug eluting embolic beads for transarterial chemoembolization in unresectable hepatocellular carcinoma.
AASLD LiverLearning®, Mohamed Shoreibah, 144252
Knockout of microRNA-21 increases high fat diet-induced lipid accumulation, biliary damage, and liver fibrosis via modulation of the SREBP1/HMGCR pathway
AASLD LiverLearning®, Lindsey Kennedy, 144508
Febuxostat prevents diet-induced steatohepatitis and insulin resistance in mice: A comparison with allopurinol
AASLD LiverLearning®, Tomoki Nishikawa, 144509
Interleukin-33 influence the progression of NASH by acting on monocytes
AASLD LiverLearning®, Jingmin Zhao, 144510
When imaging and explant pathology conflict: defining the risk of false-positive hepatocellular carcinoma in recipients transplanted with T2 MELD exceptions
AASLD LiverLearning®, Therese Bittermann, 144265
Delta MELD as a predictor of early outcome in adult-to-adult living donor liver transplantation
AASLD LiverLearning®, murat dayangac, 144266
Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States- a 4.5 Year Single-Center Experience
AASLD LiverLearning®, Gene Im, 144267
Factors Predicting Discordance Between Pretransplant Imaging Stage of Hepatocellular Carcinoma and Post-transplant Pathologic Stage
AASLD LiverLearning®, Brett Ecker, 144268
Hepatitis E virus infection and hepatic graft versus host disease in allogeneic hematopoietic stem cell transplantation recipients
AASLD LiverLearning®, Donna Bezuur, 144524
Daclatasvir in combination with other DAAs achieves high rate of virological clearance with excellent safety profile in liver tranplanted patients for hepatitis C
AASLD LiverLearning®, Raffaella Lionetti, 144525
Variation in Demographics and Comorbidities in HCV Liver Transplant Recipients within UNOS Regions
AASLD LiverLearning®, George Cholankeril, 144526
Effects of Recipient Size and Allograft Type on Pediatric Liver Transplantation for Biliary Atresia
AASLD LiverLearning®, Sophoclis Alexopoulos, 144281
Donor Diabetes Mellitus And Prolonged Cold Ischemia have a Synergistic Effect on Graft Failure After Liver Transplantation
AASLD LiverLearning®, Paulo N Martins, 144282
Kinetic AFP model analysis in patients awaiting liver transplantation (LT) for hepatocellular carcinoma (HCC): a risk factor for microvascular invasion and recurrence
AASLD LiverLearning®, Lucile Boivineau, 144283
Similar Donor and Recipient Outcomes After Left Lobe and Right Lobe Living Donor Liver Transplantation
AASLD LiverLearning®, Tiffany Wong, 144284
Current trends in characteristics of patients listed for liver transplantation will lead to higher rates of waitlist removal due clinical deterioration
AASLD LiverLearning®, A. Sidney Barritt IV, 144297
Hepatocellular Carcinoma is the Leading Indication in Liver Transplant Registrants and Recipients in the United States
AASLD LiverLearning®, Ju Dong Yang, 144298
Evaluating Liver Biopsy Predictors for Outcomes in Transplant Recipients with Cardiac/ Liver Disease
AASLD LiverLearning®, Tatyana Kushner, 144299
2-dimensional shear wave elastography rather than HVPG significantly improves MELD-Na to predict survival in decompensated cirrhosis patients
AASLD LiverLearning®, Maja Thiele, 144300
Total Skeletal Muscle Compared to Psoas Muscle Evaluation for the Assessment of Sarcopenia in Cirrhosis: A Multi-Center Study from the FLEXIT Consortium
AASLD LiverLearning®, Aldo J Montano-Loza, 144313
Comparative effectiveness of different pharmacological interventions for the treatment of minimal hepatic encephalopathy: A Systematic review with network meta-analysis
AASLD LiverLearning®, Radha Dhiman, 144314
Prevalence and Correlation of Diabetes with Severity of Chronic Liver Disease and Utility of HBA1C in these Patients as Compared with Oral Glucose Tolerance Test
AASLD LiverLearning®, Tejasav Sehrawat, 144315
Hepatocellular Carcinoma amongst Cirrhosis: Trends in Hospitalization and Inpatient Mortality in United States
AASLD LiverLearning®, Kalpit Devani, 144316
Hepato-Adrenal Syndrome is Associated with Increased Length of Stay
AASLD LiverLearning®, Christina Lindenmeyer, 144329
Long term follow-up progresses of patients after autologous bone marrow cell infusion for decompensated liver cirrhosis
AASLD LiverLearning®, Kwan Sik Lee, 144330
Palliative Care Utilization is Associated with Reduced Costs and Reduced Procedures in the Setting of Hepatocellular Carcinoma with Mortality: A Study of the National Inpatient Sample
AASLD LiverLearning®, Anne Liu, 144331
Prevalence, Predictors And Outcomes Of Hypoxic Hepatitis In Critically Ill Cirrhotics-A Single Center Prospective Study
AASLD LiverLearning®, RAKHI MAIWALL, 144332
AT-337 and AT-511: Novel Potent and Selective Pan-genotypic Purine Nucleotide Prodrug Inhibitors of the HCV Polymerase
AASLD LiverLearning®, Steven Good, 144345
Mechanisms that Control Cyp4a10 and Cyp4a14 Expression by Nuclear Receptor SHP and Rev-Erbα in Alcoholic Fatty Liver
AASLD LiverLearning®, Zhihong Yang, 144090
Safety, Tolerability, Pharmacokinetics (PK) and Antiviral Activity of EDP-494, a Potent Pan-Genotypic Cyclophilin (Cyp) Inhibitor for Chronic Hepatitis C Infection (CHC), in Healthy Subjects (HS) and in CHC Genotype 1 and 3 Patients: Preliminary Result
AASLD LiverLearning®, Edward Gane, 144346
FOXO3-dependent, M1-selective hepatic macrophage apoptosis is a normal mechanism that allows the liver to tolerate alcohol with minimal or no inflammation
AASLD LiverLearning®, Zhuan Li, 144091
Triple Combination Drug Interaction Studies of the Nucleotide Analog, AL-335, in Combination with Simeprevir and Odalasvir Demonstrate Significant Synergy in the Hepatitis C Virus (HCV) Subgenomic Replicon System
AASLD LiverLearning®, Hua Tan, 144347
Restoration of bile acid homeostasis improves alcoholic liver disease in mice
AASLD LiverLearning®, Phillipp Hartmann, 144092
Towards a Single Treatment Cure for HCV: Reformulation of the Pan-genotypic NNI GSK2878175 as a Long Acting Parenteral (LAP) and In Vivo Proof of Concept
AASLD LiverLearning®, Martin Leivers, 144348
Hepatitis C virus inhibits tumor suppressor p53 via host protein kinase R-dependent mechanisms
AASLD LiverLearning®, David McGivern, 144361
Alcoholic Hepatitis and Disease Severity Are Associated With Distinct Shifts in Fecal Microbial Ecology
AASLD LiverLearning®, Puneet Puri, 144106
MicroRNA-130a regulates HCV and HBV replication through a central metabolic pathway
AASLD LiverLearning®, Xiaoqiong Duan, 144362
The Role of Protein Carbonylation in Progression of Alcoholic Liver Disease in Male GSTA4-4 -/- Mice
AASLD LiverLearning®, Colin Shearn, 144107
Elevated plasma miR-24, miR-223, and PCSK9 levels in hepatitis C-infected patients who achieve a treatment-based viral cure
AASLD LiverLearning®, Anastasia Hyrina, 144363
PNPLA3 G/G genotype doubles the mortality risk of patients with portal hypertension due to fatty liver disease
AASLD LiverLearning®, Mattias Mandorfer, 144108
Changes in NS3/4A and NS5A resistance-associated variants of hepatitis C virus after treatment failure with direct-acting antiviral(s).
AASLD LiverLearning®, Hoang Hai, 144377
The mortality burden of alcoholic liver disease in alcohol-related hospitalizations.
AASLD LiverLearning®, George Cholankeril, 144122
IL-22 mediates liver fibrosis in patients with chronic hepatitis C by inducing IL-20 production
AASLD LiverLearning®, Jingmin Zhao, 144378
Acute Alcoholic Hepatitis has Comparable Survival following Liver Transplantation to Other Causes of Acute Liver Failure
AASLD LiverLearning®, George Cholankeril, 144123
Enhanced Natural Killer Cell Activity and Natural Resistance to Viral Infection amongst Irish Women Exposed to Hepatitis C Virus via Contaminated Anti-D Immunoglobulin
AASLD LiverLearning®, Mark Robinson, 144379
Excess Adiposity in Alcoholic Hepatitis Increases Mortality and Morbidity
AASLD LiverLearning®, Richard Parker, 144124